Vanguard Group’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Vanguard Group’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,144	Closed	-$521K	–	4638
2023 Q2	$521K	Sell	23,144 -3	-0%	-$22	﹤0.01%	4112
2023 Q1	$280K	Hold	23,147	–	–	﹤0.01%	4268
2022 Q4	$105K	Hold	23,147	–	–	﹤0.01%	4386
2022 Q3	$152K	Buy	23,147 +4,213	+22%	+$38.5K	﹤0.01%	4456
2022 Q2	$204K	Sell	18,934 -4,951	-21%	-$66.6K	﹤0.01%	4467
2022 Q1	$456K	Sell	23,885 -16,850	-41%	-$375K	﹤0.01%	4419
2021 Q4	$1.46M	Buy	40,735 +9,721	+31%	+$553K	﹤0.01%	4151
2021 Q3	$2.28M	Buy	31,014 +3,490	+13%	+$269K	﹤0.01%	4022
2021 Q2	$3.84M	Sell	27,524 -840	-3%	-$148K	﹤0.01%	3727
2021 Q1	$8.24M	Buy	28,364 +25,672	+954%	+$10.2M	﹤0.01%	3258
2020 Q4	$1.68M	Buy	+2,692	New	+$1.22M	﹤0.01%	3707

Other funds holding SGTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Group's SGTX Position: Q3 2023 in Review

Vanguard Group sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 23,144 shares — an estimated $521K sold.

Vanguard Group first reported a position in SGTX in Q4 2020 and held it in 11 quarters. The position peaked at $8.24M in Q1 2021. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

Vanguard Group reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Vanguard Group sold 23,144 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $521K.
Vanguard Group first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Vanguard Group's Sigilon Therapeutics, Inc. Common Stock position peaked at $8.24M in Q1 2021.
1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.